1. A 38-year-old woman with severe asthma (FEV1 52% predicted, on high-dose ICS/LABA combination therapy) presents to the ED with acute bronchospasm after accidentally ingesting a neighbor's metoprolol 100 mg tablet. Her SpO2 is 88%, she has audible wheeze, HR 54 bpm, BP 108/72 mmHg. Which of the following most accurately explains why metoprolol has precipitated bronchospasm despite being a beta-1 selective agent, identifies the pharmacological mechanism of bronchospasm, and guides acute management?

• A) Metoprolol has precipitated bronchospasm because at the dose ingested (100 mg acutely), plasma concentrations greatly exceed those achieved with standard oral dosing -- at high plasma concentrations, the beta-1:beta-2 selectivity ratio of metoprolol (approximately 20-50:1) means that while beta-1 blockade dominates, a clinically significant degree of beta-2 blockade occurs in bronchial smooth muscle; beta-2 blockade removes the sympathetic beta-2 bronchodilatory counterbalance to resting vagal M3-mediated bronchomotor tone, allowing unopposed vagal bronchoconstriction; in a patient with severe asthma and pre-existing bronchial hyperresponsiveness, even modest beta-2 blockade produces severe clinically significant airway narrowing; the bradycardia (HR 54) and hypotension reflect the intended beta-1 effects at this supratherapeutic dose; management: inhaled SABA (salbutamol -- competes with metoprolol at beta-2 receptors since metoprolol is a competitive antagonist; high doses may partially overcome the blockade); IV magnesium sulfate for severe bronchospasm; IV glucagon (activates Gs-cAMP in bronchial smooth muscle via glucagon receptors, bypassing the blocked beta-2 receptor -- a non-adrenergic bronchodilatory mechanism unaffected by beta-blockade); ipratropium (blocks the vagal M3 bronchomotor tone that is unopposed by the blocked beta-2 counterbalance); avoid epinephrine if possible (alpha-1 vasoconstriction may produce hypertension in the context of beta-2 blockade); heliox and non-invasive ventilation as needed.
• B) Metoprolol is a fully selective beta-1 antagonist that cannot produce bronchospasm under any circumstances -- the bronchospasm in this patient is a coincidental asthma exacerbation unrelated to the metoprolol ingestion; the beta-1 selectivity of metoprolol is absolute (a property certified by the FDA approval process for use in any patient regardless of respiratory status); inhaled SABA is the appropriate treatment for the coincidental asthma exacerbation without any modification for the metoprolol ingestion.
• C) Metoprolol directly activates mast cell beta-2 receptors producing histamine release -- this paradoxical beta-2 agonist-mediated mast cell degranulation is the mechanism of bronchospasm with cardioselective beta-blockers; the mechanism differs from non-selective beta-blocker bronchospasm, which is from vagal M3 unopposed bronchomotor tone; treatment of metoprolol-induced mast cell bronchospasm requires IV antihistamines (diphenhydramine) and epinephrine rather than SABA or ipratropium.
• D) Metoprolol blocks both beta-1 and beta-2 receptors with dose-dependent loss of cardioselectivity; at toxic doses, beta-2 blockade in bronchial smooth muscle removes the sympathetic bronchodilatory counterbalance, causing bronchoconstriction from unopposed vagal M3 tone; glucagon IV (bypassing the blocked beta-2 receptor via Gs-cAMP) and ipratropium (blocking the unopposed M3 bronchoconstrictor) are both pharmacologically rational; SABA (competing with the reversible metoprolol at beta-2) at high doses may partially restore bronchodilation; the bradycardia warrants atropine IV if hemodynamically significant, or glucagon IV for both cardiac and bronchial beta-blockade reversal.
• E) The bronchospasm results from metoprolol blocking presynaptic beta-2 autoreceptors on vagal nerve terminals in the bronchial wall -- presynaptic beta-2 activation normally inhibits ACh release from vagal terminals, reducing bronchomotor tone; metoprolol blocking these presynaptic beta-2 autoreceptors removes the inhibition of ACh release, flooding bronchial M3 receptors with excess ACh and producing severe bronchoconstriction; this mechanism is unique to cardioselective beta-blockers (which retain some beta-2 activity just sufficient to block presynaptic but not postsynaptic beta-2 receptors).

2. A 55-year-old man with Parkinson disease is on levodopa/carbidopa. He is started on metoclopramide for gastroparesis. Two days later he develops marked worsening of his parkinsonian symptoms (rigidity, bradykinesia). His neurologist recognizes a drug interaction. Which of the following most accurately identifies the receptor mechanism of the interaction and the pharmacological rationale for the alternative prokinetic agent?

• A) Metoclopramide is a D2 receptor antagonist -- it crosses the blood-brain barrier and blocks striatal D2 receptors; in Parkinson disease, nigrostriatal dopaminergic tone is already severely reduced from dopaminergic neuron degeneration; central D2 blockade by metoclopramide further reduces dopaminergic signaling in the striatum, dramatically worsening parkinsonian motor symptoms (rigidity, bradykinesia, tremor); metoclopramide also blocks D2 receptors in the CTZ (antiemetic mechanism) and accelerates gastric emptying through peripheral D2 antagonism and cholinergic facilitation; the alternative prokinetic agent is domperidone (D2 antagonist that does not cross the blood-brain barrier due to its large molecular weight and poor lipid solubility) or prucalopride (5-HT4 receptor agonist in the gut wall that enhances peristalsis without any dopamine receptor activity); domperidone is the preferred alternative for Parkinson gastroparesis specifically.
• B) Metoclopramide antagonizes the therapeutic effect of levodopa/carbidopa by blocking DOPA decarboxylase in the gut wall -- metoclopramide was originally developed as a peripheral decarboxylase inhibitor and retains residual AADC inhibitory activity; this peripheral decarboxylase inhibition reduces intestinal conversion of levodopa to dopamine, increasing the fraction that reaches the brain but also altering the kinetics of central levodopa absorption; the worsened parkinsonism results from the altered pharmacokinetics producing erratic plasma levodopa levels with off-period prolongation.
• C) Metoclopramide inhibits tyrosine hydroxylase in peripheral dopaminergic neurons, reducing the synthesis of the dopamine precursor L-DOPA in the gut wall and adrenal medulla; since gut-synthesized L-DOPA is a significant source of the circulating L-DOPA pool that supplements the oral levodopa dose, tyrosine hydroxylase inhibition by metoclopramide reduces the effective levodopa dose; domperidone does not inhibit tyrosine hydroxylase and is therefore the safe alternative.
• D) Metoclopramide blocks both central D2 receptors (worsening parkinsonism) and peripheral D2 receptors on the lower esophageal sphincter and gastric antrum (the prokinetic mechanism); domperidone has an identical mechanism of D2 blockade but a molecular weight of 426 Da compared to metoclopramide's 300 Da -- the larger size of domperidone prevents it from crossing the blood-brain barrier through tight junctions despite similar lipid solubility; the 126 Da molecular weight difference is the sole pharmacological basis for the CNS safety advantage of domperidone over metoclopramide in Parkinson patients.
• E) Metoclopramide increases striatal dopamine release through a dopamine reuptake inhibition mechanism -- it blocks the dopamine transporter (DAT) in the striatum, increasing synaptic dopamine concentrations; paradoxically, excessive synaptic dopamine in Parkinson disease worsens motor symptoms by activating D1 receptors which oppose the therapeutic D2-mediated effects of levodopa; the worsened parkinsonism therefore reflects D1 receptor overstimulation from metoclopramide-mediated DAT blockade rather than D2 receptor antagonism.

3. A 67-year-old man with COPD (FEV1 48% predicted), hypertension, and BPH is on tiotropium, tamsulosin, and amlodipine. His cardiologist adds bisoprolol 2.5 mg daily for newly diagnosed heart failure with reduced ejection fraction (EF 32%). Three days later he presents with worsening dyspnea and FEV1 has fallen from 48% to 41% predicted. Which of the following most accurately identifies the pharmacological mechanism of the pulmonary deterioration and the evidence-based management strategy for HFrEF in a patient with significant COPD?

• A) Bisoprolol (beta-1 selective, selectivity ratio approximately 75:1) has precipitated bronchoconstriction through dose-dependent loss of beta-1 selectivity at the 2.5 mg dose -- at even this low starting dose, the absolute beta-2 occupancy in the bronchial smooth muscle of a patient with FEV1 48% predicted and pre-existing airway hyperresponsiveness is sufficient to remove the sympathetic beta-2 bronchodilatory counterbalance, revealing the full magnitude of resting vagal M3-mediated bronchomotor tone; the FEV1 decline from 48% to 41% (7 percentage points, approximately 15% relative decline) represents clinically significant beta-2-mediated bronchoconstriction; management: bisoprolol is NOT absolutely contraindicated in COPD -- multiple randomized controlled trials (BEST, COPERNICUS, MERIT-HF) have confirmed that cardioselective beta-1 blockers (bisoprolol, metoprolol succinate, carvedilol) improve survival, reduce hospitalization, and improve EF in HFrEF even in patients with COPD; bisoprolol in COPD with HFrEF should be: started at the lowest possible dose (1.25 mg daily), titrated extremely slowly (doubling dose no more than every 2-4 weeks), with spirometry monitoring at each dose change; if bronchoconstriction persists, consider metoprolol succinate (slightly lower beta-1 selectivity than bisoprolol but extensive evidence base) or nebivolol (beta-1 selective with NO-mediated vasodilation); non-selective beta-blockers (carvedilol) should be avoided in patients with FEV1 below 50% predicted; bronchodilator therapy should be optimized (adding or increasing LAMA, LABA if not contraindicated).
• B) Bisoprolol has no bronchopulmonary effects in COPD -- it is completely beta-1 selective at all doses and cannot produce any beta-2-mediated bronchoconstriction; the FEV1 decline is from natural COPD progression coincidentally occurring three days after bisoprolol initiation; the timing is coincidental; bisoprolol should be continued at full therapeutic doses without any dose modification or spirometry monitoring; COPD is not a contraindication or a caution for any beta-1 selective beta-blocker at any dose.
• C) Beta-blockers of any selectivity are absolutely contraindicated in COPD -- the 2023 ESC heart failure guidelines list COPD with FEV1 below 50% as an absolute contraindication to all beta-blockers including the most cardioselective agents; this patient should be managed with ivabradine (HCN channel blocker) and sacubitril/valsartan (ARNI) as a beta-blocker substitute; these agents improve outcomes in HFrEF without any pulmonary adverse effects.
• D) Bisoprolol produces bronchoconstriction through beta-2 receptor blockade in bronchial smooth muscle even at low doses in severe COPD; the appropriate evidence-based response is NOT to discontinue bisoprolol but to: reduce the dose to 1.25 mg daily and titrate more slowly; add or optimize inhaled bronchodilator therapy (increasing tiotropium to twice daily, adding an inhaled LABA such as salmeterol or formoterol to the regimen -- beta-2 agonist LABAs can partially compete with bisoprolol at beta-2 receptors and restore bronchodilatory tone); cardioselective beta-blockers carry a class I indication for HFrEF regardless of COPD severity -- the mortality benefit in HFrEF outweighs the modest pulmonary risk; absolute contraindication is limited to severe reactive asthma (not COPD); the spirometric decline should be monitored at each dose increment.
• E) Bisoprolol produces bronchoconstriction via a mechanism entirely unrelated to beta-2 receptor blockade -- bisoprolol blocks alpha-1 adrenergic receptors in the bronchial vasculature, producing mucosal congestion and mechanical airway narrowing; the correct management is to add an alpha-1 agonist (phenylephrine nasal spray) to maintain bronchial vasoconstriction; increasing the LABA dose is counterproductive because LABAs act via beta-2 receptors which are unaffected by bisoprolol.

4. A 42-year-old woman with Raynaud phenomenon and newly diagnosed hypertension is started on nifedipine extended-release 30 mg daily. Her internist also considers adding prazosin for Raynaud symptom control but is advised against this by the pharmacology consultant. Two months later her BP remains 158/96 mmHg despite nifedipine 60 mg daily. The internist considers adding doxazosin. Which of the following most accurately explains the receptor mechanism by which an alpha-1 blocker could treat both hypertension and Raynaud phenomenon, the pharmacological reason prazosin was initially discouraged, and the advantage of doxazosin over prazosin?

• A) Alpha-1 blockers (prazosin, doxazosin) treat both hypertension and Raynaud by blocking alpha-1 adrenergic receptors -- in hypertension, alpha-1 blockade reduces peripheral vascular resistance by preventing NE-mediated Gq-IP3-calcium-MLCK-dependent vasoconstriction in arteriolar smooth muscle; in Raynaud phenomenon, the episodic digital vasospasm is mediated by excessive alpha-2 receptor activation (alpha-2C receptors translocate from intracellular compartments to the cell surface in response to cold, dramatically increasing alpha-2-mediated vasoconstriction at low temperatures) -- while alpha-1 blockers do not directly block alpha-2 receptors, they reduce the baseline vascular tone, providing a more dilated vascular set-point that makes complete vasospasm less likely at any given level of alpha-2 activation; prazosin was initially discouraged because of its pronounced first-dose hypotension -- prazosin has a rapid onset and short elimination half-life (2-3 hours) producing steep peaks in alpha-1 blockade after each dose that trigger pronounced baroreceptor-mediated reflex tachycardia and orthostatic hypotension, particularly after the first dose; doxazosin has a longer elimination half-life (20-22 hours), producing a more gradual onset, smoother plasma concentration profile, less pronounced first-dose hypotension, and once-daily dosing; the XL formulation of doxazosin uses a gastrointestinal therapeutic system for even more gradual absorption, further reducing orthostatic hypotension risk.
• B) Alpha-1 blockers cannot treat Raynaud phenomenon because Raynaud vasospasm is mediated exclusively by alpha-2 adrenergic receptors -- only alpha-2 antagonists (yohimbine, moxisylyte) are pharmacologically rational for Raynaud; prazosin was discouraged not because of first-dose hypotension but because alpha-1 blockade worsens Raynaud by removing the vascular tone that prevents paradoxical cold-induced alpha-2 vasodilation from becoming a net vasodilatory response; doxazosin is preferred over prazosin for hypertension but has the same contraindication for Raynaud as prazosin.
• C) Prazosin and doxazosin are identical in their pharmacodynamic receptor profiles (both selective alpha-1A, alpha-1B, alpha-1D antagonists) -- the clinical difference is entirely pharmacokinetic; prazosin is absorbed more rapidly and has a shorter half-life (2-3 hours) producing peaks and troughs with three-times-daily dosing; doxazosin has a half-life of 20-22 hours allowing once-daily dosing with more stable plasma levels; the first-dose hypotension risk of prazosin is clinically significant and led to its replacement by doxazosin and terazosin in clinical practice; both can be used for hypertension and as adjuncts to reduce digital vasospasm frequency in Raynaud.
• D) Alpha-1 blockade treats hypertension by reducing cardiac output through negative chronotropic effects at the SA node -- cardiac alpha-1 receptors are the primary mediators of exercise-induced tachycardia, and prazosin blocking these receptors reduces maximum heart rate; the blood pressure reduction reflects primarily reduced cardiac output rather than peripheral vasodilation; for Raynaud, alpha-1 blockade prevents exercise-induced digital vasoconstriction which is alpha-1-mediated; the concern about prazosin was that it blocks alpha-1 receptors in the bladder neck, causing urinary incontinence in women -- doxazosin has better bladder selectivity and is preferred in female patients.
• E) The pharmacological rationale for using an alpha-1 blocker in Raynaud is to competitively block alpha-1 receptors on digital arteries that are also activated by the 5-HT2A serotonin receptor signaling pathway -- Raynaud vasospasm involves both alpha-1 adrenergic and 5-HT2A pathways; prazosin blocks alpha-1 and incidentally 5-HT2A receptors; doxazosin lacks the 5-HT2A blocking activity of prazosin and is therefore less effective for Raynaud but preferred for hypertension because its lack of 5-HT2A blockade avoids the anti-serotonergic side effects (weight gain, sedation) seen with prazosin.

5. A 29-year-old competitive cyclist is prescribed a beta-blocker for newly diagnosed hypertrophic obstructive cardiomyopathy (HOCM). His cardiologist is choosing between propranolol and metoprolol succinate. Which of the following most accurately explains the pharmacological rationale for beta-blockade in HOCM, the specific advantages and disadvantages of non-selective versus cardioselective blockade in this setting, and the pharmacokinetic differences between propranolol and metoprolol succinate?

• A) The rationale for beta-blockade in HOCM: the dynamic left ventricular outflow tract (LVOT) obstruction in HOCM is worsened by sympathetic beta-1 activation -- increased heart rate reduces diastolic filling time (reducing LV volume, worsening obstruction from Venturi effect and systolic anterior motion of the mitral valve), increased contractility increases the velocity of LV ejection (worsening the Venturi-mediated anterior movement of the mitral valve leaflet into the LVOT), and peripheral beta-2-mediated vasodilation reduces afterload (less LV afterload reduces LV outflow impedance, worsening dynamic obstruction); beta-blockade addresses all three: reducing heart rate (improving diastolic filling and increasing LV end-diastolic volume), reducing contractility (reducing ejection velocity and SAM), and avoiding the vasodilation that worsens obstruction; propranolol (non-selective) blocks both beta-1 (therapeutic for HOCM) and beta-2 (also therapeutic in HOCM -- preventing peripheral vasodilation that worsens obstruction and preventing exercise-induced tachycardia from beta-2-mediated vasodilation); metoprolol succinate (cardioselective beta-1) blocks cardiac beta-1 (reducing HR and contractility) but preserves beta-2-mediated vasodilation -- potentially allowing more vasodilation during exercise that could worsen LVOT obstruction; however, at therapeutic doses metoprolol succinate produces adequate LVOT obstruction reduction and is better tolerated by competitive athletes (preserving beta-2-mediated skeletal muscle vasodilation and glycogenolysis for exercise performance); propranolol pharmacokinetics: high hepatic first-pass extraction (~60-70%), large volume of distribution, lipophilic (CNS penetration -- sedation, vivid dreams), half-life 4-6 hours requiring multiple daily dosing, extensive CYP2D6 metabolism; metoprolol succinate pharmacokinetics: extended-release formulation producing once-daily dosing with stable plasma levels, CYP2D6 metabolism, moderate lipophilicity (less CNS penetration than propranolol), half-life of extended-release formulation effectively 24 hours.
• B) Beta-blockade is contraindicated in HOCM because reducing cardiac contractility in a hypertrophied ventricle produces severe systolic dysfunction -- the primary treatment for HOCM is calcium channel blockade (verapamil) which reduces contractility and heart rate by a mechanism that does not worsen outflow obstruction; beta-blockers should never be used in HOCM because their negative inotropic effect worsens myocardial ischemia from the thickened interventricular septum compressing intramural coronary arteries during beta-blocker-enhanced diastolic stiffness.
• C) The therapeutic rationale for beta-blockade in HOCM focuses primarily on antiarrhythmic effects rather than hemodynamic effects -- ventricular arrhythmias from the disorganized hypertrophied myocardium are the primary cause of sudden cardiac death in HOCM; beta-blockers suppress these arrhythmias via beta-1 receptor blockade at the ventricular myocardium; the hemodynamic effect on LVOT obstruction is a minor secondary benefit; non-selective propranolol is preferred because it has additional membrane-stabilizing (local anesthetic) properties that suppress ventricular arrhythmias through sodium channel blockade in addition to beta-1 blockade.
• D) Propranolol is preferred over metoprolol in HOCM because non-selective beta-2 blockade prevents peripheral vasodilation that would worsen dynamic LVOT obstruction during exercise -- this is the primary pharmacological argument for non-selective over cardioselective agents in HOCM; the disadvantage for a competitive cyclist is the significant impairment of exercise capacity from beta-2 blockade (blocking skeletal muscle vasodilation, glycogenolysis, and lipolysis); metoprolol succinate is acceptable if the patient cannot tolerate the exercise limitation of propranolol but requires careful monitoring of LVOT gradient during exercise echo stress testing to confirm adequate obstruction control.
• E) Both propranolol and metoprolol are equivalent in HOCM because the dynamic obstruction is caused by alpha-1-mediated increased ventricular wall tension rather than beta-adrenergic activation -- beta-blockers reduce LVOT obstruction through their alpha-1 blocking off-target activity (propranolol and metoprolol both have modest alpha-1 blocking properties at standard doses); the truly effective agent for HOCM would be a pure alpha-1 blocker (doxazosin) that directly reduces ventricular wall tension without any effect on heart rate that would worsen arrhythmia risk.

6. A 52-year-old woman with type 1 diabetes managed with insulin pump therapy presents to her endocrinologist reporting multiple episodes of "silent" hypoglycemia -- she has found herself at glucose levels of 38-48 mg/dL without experiencing her usual warning symptoms of tremor and palpitations. Review of her medications reveals she was recently started on atenolol 50 mg daily for hypertension. Which of the following most accurately explains the receptor-level mechanism by which atenolol masks hypoglycemia warning symptoms, identifies which warning symptoms are preserved, and recommends the pharmacological management of her hypertension?

• A) Atenolol (cardioselective beta-1 blocker) masks two major adrenergic hypoglycemia warning symptoms: tachycardia (from beta-1 SA node blockade -- the normal baroreceptor-mediated reflex tachycardia in response to hypoglycemia-induced low blood pressure is abolished) and palpitations (from beta-1 blockade -- subjective awareness of heart rate elevation is lost); tremor (from beta-2 blockade of skeletal muscle contractile response to hypoglycemia) -- atenolol at standard doses (50 mg) has sufficient beta-1 selectivity to preserve tremor because tremor is mediated by beta-2 receptors and atenolol preferentially blocks beta-1; diaphoresis (sweating) is the critical preserved warning symptom -- sweating is driven by sympathetic CHOLINERGIC innervation of eccrine sweat glands (M3 receptors on eccrine secretory coils, not adrenergic) and is therefore unaffected by any beta-blocker; atenolol also impairs hepatic glycogenolysis (beta-2-mediated) partially, but with beta-1 selectivity at standard doses this effect is less than with non-selective agents; management: replace atenolol with a non-beta-blocking antihypertensive (ACE inhibitor lisinopril, ARB, or CCB amlodipine) to eliminate all hypoglycemia warning masking; if beta-blockade is required for a compelling cardiac indication, use the most cardioselective available agent (bisoprolol 75:1 beta-1:beta-2 selectivity) at the lowest effective dose with reinforced hypoglycemia awareness training; counsel the patient that diaphoresis is her one remaining reliable warning sign.
• B) Atenolol masks all hypoglycemia warning symptoms completely -- neither tremor, palpitations, tachycardia, nor diaphoresis occurs during hypoglycemia in patients on atenolol; all four warning symptoms are mediated by beta-1 adrenergic receptors; atenolol must be replaced with a non-adrenergic antihypertensive because no adrenergic drug of any selectivity can be safely used in insulin-requiring diabetic patients.
• C) Atenolol masks tachycardia and palpitations (beta-1 SA node blockade) but also masks tremor (because atenolol at 50 mg exceeds its beta-1 selectivity threshold and produces significant beta-2 blockade in skeletal muscle) and also masks diaphoresis (because atenolol blocks the beta-1 receptors on sweat gland sympathetic preganglionic neurons that regulate eccrine gland activation) -- all four warning signs are masked; the only unmasked warning sign is the subjective cognitive symptoms of neuroglycopenia (confusion, difficulty concentrating) which are not adrenergically mediated; the appropriate replacement is ACE inhibitor or ARB.
• D) Atenolol masks tachycardia and palpitations through beta-1 receptor blockade at the SA node and does not mask tremor (preserved -- tremor is beta-2 mediated and atenolol at 50 mg maintains relative beta-1 selectivity) and does not mask diaphoresis (preserved -- eccrine sweat glands are sympathetic cholinergic, not adrenergic); atenolol also partially masks the hypoglycemia counterregulatory glycogenolysis response by reducing beta-2-mediated hepatic glycogen breakdown, potentially prolonging the depth and duration of hypoglycemia; the recommended management is to replace atenolol with an ACE inhibitor, ARB, or amlodipine if the indication is hypertension alone; if beta-blockade is required for a cardiac indication, use bisoprolol at the lowest effective dose with careful hypoglycemia monitoring and reinforced diaphoresis-based hypoglycemia awareness.
• E) Atenolol does not mask any hypoglycemia warning symptoms -- the warning symptoms of hypoglycemia (tremor, tachycardia, palpitations, diaphoresis) are mediated entirely by parasympathetic activation (vagal cholinergic system detecting glucose deficiency in the brainstem) rather than by the adrenergic sympathomimetic response to low blood glucose; atenolol blocking adrenergic receptors has no effect on the vagally mediated hypoglycemia warning response; the silent hypoglycemia in this patient is from diabetic autonomic neuropathy damaging the vagal brainstem glucose-sensing pathway, and the atenolol initiation is temporally coincidental.